ONC201 and Paclitaxel in Treating Patients With Platinum-Resistant Refractory or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04055649 |
|
Recruitment Status :
Not yet recruiting
First Posted : August 14, 2019
Last Update Posted : August 14, 2019
|
Sponsor:
Ira Winer
Information provided by (Responsible Party):
Ira Winer, Barbara Ann Karmanos Cancer Institute
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Not yet recruiting |
|---|---|
| Estimated Primary Completion Date : | January 1, 2020 |
| Estimated Study Completion Date : | June 1, 2020 |